Segment Information (Tables)

6 Months Ended

Dec. 31, 2023

Schedule of Revenue by Segment and Reconciling Items

The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):


	Three Months Ended December 31,				Six Months Ended December 31,
	2023		2022		2023		2022
Net revenue by segment
Sleep and Respiratory Care	$	1,017,855	$	916,981	$	1,980,892	$	1,761,424
Software as a Service	144,946		116,763		284,230		222,614
Total	$	1,162,801	$	1,033,744	$	2,265,122	$	1,984,038

Depreciation and amortization by segment
Sleep and Respiratory Care	$	21,956	$	18,533	$	42,475	$	38,301
Software as a Service	2,725		2,097		5,485		4,009
Amortization of acquired intangible assets and corporate assets	20,103		17,137		41,758		31,730
Total	$	44,784	$	37,767	$	89,718	$	74,040

Net operating profit by segment
Sleep and Respiratory Care	$	426,393	$	373,367	$	816,808	$	726,027
Software as a Service	41,787		28,814		73,045		53,581
Total	$	468,180	$	402,181	$	889,853	$	779,608

Reconciling items
Corporate costs	$	102,673	$	96,707	$	206,052	$	183,326
Amortization of acquired intangible assets	19,834		16,868		41,220		31,193
Restructuring expenses	64,228		—		64,228		—
Masks with magnets field safety notification expenses (1)	6,351		—		6,351		—
Astral field safety notification expenses (2)	—		—		7,911		—
Acquisition related expenses	—		8,412		—		9,157
Interest expense (income), net	13,805		10,338		28,762		17,472
(Gain) Loss attributable to equity method investments	(739)		2,826		3,156		4,853
(Gain) loss on equity investments	1,888		(8,368)		2,491		(5,088)
Other, net	686		1,707		(1,963)		3,211
Income before income taxes	$	259,454	$	273,691	$	531,645	$	535,484

(1) The masks with magnets field safety notification expenses relate to estimated costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets.

(2) The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.